Virax Biolabs Group Ltd (VRAX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.79
- As of
Kresmion compiles this page from VRAX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Virax Biolabs Group Ltd (VRAX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-29.
See the full VRAX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VRAX on one page. Preview it with sample data, then open it live with a free account.
Preview the VRAX dossierActive events for VRAX
No recent events on VRAX in the last 180 days.
FREE, NO ACCOUNT
Every event on VRAX, as it fires
New filings, 13F moves and cross asset events on VRAX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, VRAX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
Going concern statement
VRAX's 20-F filed Jul 6, 2026 states:
As discussed in Note 1 to the consolidated financial statements, the Company's significant operating losses raise substantial doubt about its ability to continue as a going concern.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on VRAX
VRAX against its peers
VRAX's operating margin of -97344.8% ranks in the 15th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | VRAX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6331 USD | 5.8M USD | 17 | 8 |
| Revenue YoY | -96.0% | n/a | n/a | 2 |
| Gross margin | -838.2% | 55.7% | 8 | 5 |
| Operating margin | -97344.8% | -219.6% | 15 | 9 |
| Net margin | -95739.2% | -207.2% | 15 | 9 |
| Return on equity | -106.4% | -158.8% | 63 | 11 |
Peers (18): ARTL, VBIO, SCNI, MTNB, ISCO, BDRX, AGTX, ATXI, EVFM, OGEN, GOVX, ADTX, KAPA, KPTI, GNPX, EMMA, CDT, PPCB. Left out: AXIM (period gap), BBLG (no annual filing), PTIX (period gap), CLSDQ.D (no annual filing), ELAB (no annual filing), LNAI (period gap), XRTX (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (VRAX: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in VRAX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on VRAX in the last 180 days.
Upstream: SEC EDGAR filings for VRAX
Kresmion, "Virax Biolabs Group Ltd (VRAX) institutional holdings and SEC filings", data as of 2026-10-29, https://kresmion.com/research/VRAX. Upstream data: SEC EDGAR filings for VRAX.
Link to this data (HTML):
<a href="https://kresmion.com/research/VRAX">Virax Biolabs Group Ltd (VRAX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow VRAX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to VRAX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.